---
gsd_state_version: 1.0
milestone: v1.8
milestone_name: Phases
status: completed
stopped_at: Phase 63 context gathered
last_updated: "2026-06-01T01:39:44.245Z"
last_activity: 2026-05-31
progress:
  total_phases: 62
  completed_phases: 51
  total_plans: 93
  completed_plans: 87
  percent: 25
---

# Project State

## Project Reference

See: .planning/PROJECT.md (updated 2026-05-29)

**Core value:** A working cohort filter chain that reads like a clinical protocol — with logged attrition at every step and clear payer-stratified visualizations showing how patients flow from enrollment through diagnosis to treatment.

**Current focus:** Phase 61 — episode-classification-cancer-linkage-and-regimen-detection

## Current Position

Phase: 62
Plan: Not started
Status: Phase 61 complete — ready for transition to Phase 62
Progress: ▰▱▱▱▱▱▱▱▱▱ 25% (1/4 phases complete in v1.8)
Last activity: 2026-05-31

## Performance Metrics

**Velocity:**

- Total plans completed: 87 (across v1.0-v1.8)
- Average duration: varies by phase complexity
- Total execution time: ~90 hours
- Phase 61 Plan 01: 3 minutes (2 tasks, 1 script created)

**By Milestone:**

- v1.8 (Phase 61): 1 phase (in progress), 1 plan complete, started 2026-05-30
- v1.7 (Phases 55-59): 5 phases, shipped 2026-05-28
- v1.6 (Phases 45-54): 10 phases, 13 plans, shipped 2026-05-22
- v1.5 (Phases 34-37): 4 phases, 4 plans, shipped 2026-05-01
- v1.4 (Phase 33): 1 phase, 2 plans, shipped 2026-04-27
- v1.3 (Phases 29-32): 4 phases, 4 plans, shipped 2026-04-23

**Recent Trend:**

- Last milestone (v1.7): Cancer summary refinement, Gantt enhancements, death date validation
- Trend: Stable
- Current milestone (v1.8): Encounter-level cancer linkage, first-line therapy regimen identification
- Phase 61 complete: Episode classification with cancer linkage and regimen detection

*Updated after each plan completion*

## Accumulated Context

### Decisions

Decisions are logged in PROJECT.md Key Decisions table.
Recent decisions affecting current work:

- Phase 55: R/55 consolidates R/53 and R/54 into single script; first HL diagnosis date uses pmin() for true minimum across DIAGNOSIS+TUMOR_REGISTRY
- Phase 57: Cancer categories from cancer_summary.csv via PREFIX_MAP classification in Gantt export
- Phase 59: Death date validation with impossible death exclusion; HL Diagnosis pseudo-treatment rows
- v1.8: Encounter-level cancer linkage replaces patient-level; drop ICD DX from SCT detection; new Gantt files preserve existing v1 output
- [Phase 60]: Drug name resolution covers chemotherapy only (D-06)
- [Phase 60]: Both RXNORM_CUI and NDC codes resolved via R/40 functions (D-07)
- [Phase 60]: Only codes from patient data queried, not all config codes (D-08)
- [Phase 60]: Results cached in drug_name_lookup.rds; re-runs only query new codes (D-09)
- [Phase 60]: Standalone script separate from episode extraction (D-10)
- [Phase 60-01]: SCT source audit compares WITH vs WITHOUT DX codes before removal
- [Phase 60-01]: encounter_ids aggregated per episode as comma-separated string in R/44a
- [Phase 60]: Drug names joined via left_join on triggering_code, aggregated per episode as comma-separated unique sorted list
- [Phase 60]: Phase 60 audit xlsx documents ENCOUNTERID rates, SCT audit, drug name resolution in single workbook
- [Phase 61]: Encounter-level cancer linkage via ENCOUNTERID direct match + 30-day temporal fallback (D-01 through D-08)
- [Phase 61]: Regimen detection for ABVD/BV+AVD/Nivo+AVD with dropped-agent tolerance (D-09 through D-14)
- [Phase 61]: treatment_episodes.rds enriched with cancer_category, cancer_link_method, is_hodgkin, regimen_label
- [Phase 61]: Temporal availability constraints: BV+AVD post-2019, Nivo+AVD post-2024

### Pending Todos

None — Phase 61 complete, ready for Phase 62 first-line therapy analysis

### Blockers/Concerns

- PREFIX_MAP duplication across R/47, R/53, R/54, R/49 creates sync risk — consider centralizing to R/00_config.R
- ENCOUNTERID population rates are site-dependent (39-90% validated range) — requires data inspection before Phase 61 linkage strategy
- Regimen fragmentation risk: ABVD requires 4 drugs across 28-day cycle; infusion centers create separate encounters per drug

### Roadmap Evolution

v1.8 roadmap created with coarse granularity (4 phases vs research-suggested 7):

- Phase 60: Foundation (combines research Phase 60+61) - ENCOUNTERID + drug names + SCT tightening
- Phase 61: Episode Classification (combines research Phase 62+63) - Cancer linkage + regimen detection
- Phase 62: First-Line Therapy & Death Analysis (combines research Phase 64+66) - First-line ID + death tables
- Phase 63: Enhanced Gantt Export (research Phase 65) - Gantt v2 with all enhancements

## Session Continuity

Last session: 2026-06-01T01:39:44.234Z
Stopped at: Phase 63 context gathered
Resume file: .planning/phases/63-enhanced-gantt-export/63-CONTEXT.md
Next step: `/gsd:transition` to move to Phase 62 (first-line-therapy-and-death-analysis)

---
*Last updated: 2026-05-30 — Phase 61 Plan 01 complete (episode classification with cancer linkage and regimen detection)*
